Altimmune Inc ALT Q1 2026 Earnings EPS Beat Surprises to the Upside Amid Pipeline Progress ROG Q1 2026 Earnings EPS Beats Estimates by 10 Shares Edge Higher EGBN Q1 2026 Earnings EPS Surpasses Estimates by Over 43 STLD Q1 2026 Earnings Earnings Miss Estimates Despite Strong Operational Execution KULR Q3 2025 Earnings Deep Losses Miss Estimates Despite Stock Surge CVKD Q1 2026 Earnings Narrower Loss Surprises Clinical Progress Maintained